The aim is to provide guidance on managing patients with cutaneous T-cell lymphomas receiving dupilumab treatment.
Conducted a systematic review of available literature
Formed a consensus among experts in the field
Developed recommendations for clinical management
Dupilumab may unmask or worsen CTCL, especially in patients with MF and SS
The consensus offers practical recommendations for safer management of affected patients.
Abstract
Dupilumab may unmask or exacerbate CTCL, particularly MF and SS. The consensus-based recommendations offer practical guidance for the safe management of patients.